Lanthanide Radionuclide Production

稀土放射性核素生产

• 批准号: 7538452
• 负责人: JOHN M ALFORD
• 金额: $ 17.93万
• 依托单位: TDA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-01 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7538452
• 关键词: Acids; Antibodies; Area; Binding; Businesses; Carbon; Cell Nucleus; Characteristics; Chelating Agents; Chemicals; Development; Discipline of Nuclear Medicine; District of Columbia; Educational workshop; Engineering; Environment; Evaluation; Extravasation; Fast Neutrons; Fullerenes; Gamma Rays; Generations; Government; Half-Life; Human; Hydrochloric Acid; Ion Exchange; Ions; Isotopes; Label; Laboratories; Lanthanoid Series Elements; Left; Lutetium; Malignant Neoplasms; Measures; Metals; Methods; Missouri; Monoclonal Antibodies; Natural graphite; Neoplasm Metastasis; Neutrons; Nuclear Reactors; Persons; Phase; Positioning Attribute; Procedures; Process; Production; Property; Public Health; Purpose; Quality Control; Quartz; Radiation therapy; Radioactive; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rate; Reaction; Reagent; Research; Route; Running; Sampling; Scheme; Series; Soot; Source; Spectrum Analysis; Sublimation - mental defence mechanism; Techniques; Technology Transfer; Testing; Time; Titrations; Trace metal; Tube; United States Food and Drug Administration; Universities; Work; base; cancer therapy; chelation; chemical bond; cost; cost effective; day; desire; improved; irradiation; milligram; next generation; prevent; retinal rods; success

DESCRIPTION (provided by applicant): Major advances have recently been made in the development of monoclonal antibody-based radioimmunotherapy cancer treatments, and several of these next generation antibody treatments have demonstrated good efficacy in human trials and are currently awaiting FDA approval. With this new generation of highly engineered monoclonal antibodies comes the need for a wider array of commercially available radionuclides. Unfortunately, methods for producing the next generation of radioisotopes has not kept pace. This Small Business Technology Transfer Phase I project will develop an improved method for the production of radionuclides used in radiopharmaceuticals. The method will allow the economical production of a wide array of lanthanide radionuclides which can subsequently be employed for radioimmunotherapy treatments. During Phase I, a new type of Szilard-Chalmers process using pecialized lanthanide chelates will be developed and tested. The new lanthanide chelate will be synthesized in bulk quantities and then the entire production process will be tested using neutron activation at the Missouri University Research Reactor. PUBLIC HEALTH RELEVANCE: Current radioisotope production relies on isotopically purified starting materials that must be irradiated at the highest flux (most expensive) position in the central core of the nuclear reactor. If successful, TDA's new Szilard-Chalmers process is expected to lower production costs by allowing the use of non-isotopically purified starting materials that are neutron irradiated at the more cost effective low .nux positions in the reactor.

描述（由申请人提供）：最近在基于单克隆抗体的放射免疫治疗癌症治疗方面取得了重大进展，其中一些下一代抗体治疗在人体试验中表现出良好的疗效，目前正在等待FDA的批准。随着新一代高度工程化的单克隆抗体的出现，需要更广泛的商业放射性核素。不幸的是，生产下一代放射性同位素的方法并没有跟上发展的步伐。这个小企业技术转让第一阶段项目将开发一种改进的方法，用于生产用于放射性药物的放射性核素。该方法将允许经济地生产各种镧系放射性核素，这些放射性核素随后可用于放射免疫治疗。在第一阶段，将开发和测试一种新型的使用专用镧系螯合物的西拉德-查尔默斯工艺。新的镧系螯合物将被大量合成，然后整个生产过程将在密苏里大学研究反应堆使用中子激活进行测试。公共卫生相关性：目前的放射性同位素生产依赖于同位素纯化的起始材料，这些材料必须在核反应堆中心堆芯的最高通量（最昂贵）位置进行辐照。如果成功，TDA的新Szilard-Chalmers工艺有望降低生产成本，因为它允许使用非同位素纯化的起始材料，这些材料在成本更低的地方进行中子辐照。反应堆里的Nux位置。